摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-(2-deoxy-β-D-ribofuranosyl)-6-azido-3-deazapurine | 98858-28-7

中文名称
——
中文别名
——
英文名称
9-(2-deoxy-β-D-ribofuranosyl)-6-azido-3-deazapurine
英文别名
(2R,3S,5R)-5-(4-azidoimidazo[4,5-c]pyridin-1-yl)-2-(hydroxymethyl)oxolan-3-ol
9-(2-deoxy-β-D-ribofuranosyl)-6-azido-3-deazapurine化学式
CAS
98858-28-7
化学式
C11H12N6O3
mdl
——
分子量
276.255
InChiKey
JWLAIVKYAVXDES-DJLDLDEBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    94.8
  • 氢给体数:
    2
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    咪唑并[4,5-c]吡啶(3-脱氮嘌呤)及其核苷可作为免疫抑制剂和抗炎药。
    摘要:
    合成了多种咪唑并[4,5-c]吡啶(3-脱氮嘌呤)。使用这些糖苷配基作为戊糖基受体,通过涉及从适当的嘧啶核苷转移戊糖基部分的酶促方法制备相应的核糖核苷和2'-脱氧核糖核苷。对于大多数咪唑并[4,5-c]吡啶,从酶催化反应中获得的产物仅在1-位戊糖基化。然而,在4-位具有H或N 3的糖苷配基发生了一些3-戊糖基化。除了4-氨基-1H-咪唑并[4,5-c]吡啶核糖核苷的2'-脱氧同源物外,还合成了5'-脱氧和2',5'-二脱氧同源物。测试了所有糖苷配基及其核苷对培养物中哺乳动物细胞的毒性。没有一个具有明显的细胞毒性。还评估了这些化合物在体外抑制淋巴细胞介导的细胞溶解的能力。3-Deazaadenosine(23)及其2'-deoxy同系物(38)是最有效的抑制剂(ED50 = 20 microM)。除了这两个体外测试,还确定了大鼠角叉菜胸膜炎模型中炎症反应的体内抑制作用。在该体内测试中,3-脱
    DOI:
    10.1021/jm00151a022
点击查看最新优质反应信息

文献信息

  • Synthesis of 2-Deoxy-β-D-ribonucleosides and 2,3-Dideoxy-β-D-pentofuranosides on Immobilized Bacterial Cells
    作者:Ivan Votruba、Antonín Holý、Hana Dvořáková、Jaroslav Günter、Dana Hocková、Hubert Hřebabecký、Tomas Cihlar、Milena Masojídková
    DOI:10.1135/cccc19942303
    日期:——

    Alginate gel-entrapped cells of auxotrophic thymine-dependent strain of E. coli catalyze the transfer of 2-deoxy-D-ribofuranosyl moiety of 2'-deoxyuridine to purine and pyrimidine bases as well as their aza and deaza analogs. All experiments invariably gave β-anomers; in most cases, the reaction was regiospecific, affording N9-isomers in the purine and N1-isomers in the pyrimidine series. Also a 2,3-dideoxynucleoside can serve as donor of the glycosyl moiety. The acceptor activity of purine bases depends only little on substitution, the only condition being the presence of N7-nitrogen atom. On the other hand, in the pyrimidine series the activity is limited to only a narrow choice of mostly short 5-alkyl and 5-halogeno uracil derivatives. Heterocyclic bases containing amino groups are deaminated; this can be avoided by conversion of the base to the corresponding N-dimethylaminomethylene derivative which is then ammonolyzed. The method was verified by isolation of 9-(2-deoxy-β-D-ribofuranosyl) derivatives of adenine, guanine, 2-chloroadenine, 6-methylpurine, 8-azaadenine, 8-azaguanine, 1-deazaadenine, 3-deazaadenine, 1-(2-deoxy-β-D-ribofuranosyl) derivatives of 5-ethyluracil, 5-fluorouracil, and 9-(2,3-dideoxy-β-D-pentofuranosyl)hypoxanthine, 9-(2,3-dideoxy-β-D-pentofuranosyl)-6-methylpurine, and other nucleosides.

    藻酸盐凝胶包埋的辅助胸腺嘧啶依赖菌株大肠杆菌细胞催化2'-脱氧尿嘧啶的2-脱氧-D-核糖呋喃基团转移到嘌呤和嘧啶碱基以及它们的氮杂和去氮类似物。所有实验都不可避免地产生β-异构体;在大多数情况下,反应是区域特异性的,产生嘌呤中的N9-异构体和嘧啶系列中的N1-异构体。此外,2,3-二脱氧核苷酸可以作为糖基团的供体。嘌呤碱基的受体活性仅在取代上有少许影响,唯一的条件是存在N7-氮原子。另一方面,在嘧啶系列中,活性仅限于大多数短链5-烷基和5-卤代尿嘧啶衍生物的狭窄选择。含氨基的杂环碱基会发生脱氨作用;可以通过将碱基转化为相应的N-二甲氨基甲烯基衍生物来避免这种情况,然后进行氨解作用。该方法通过分离腺嘌呤、鸟嘌呤、2-氯腺嘌呤、6-甲基嘌呤、8-氮杂腺嘌呤、8-氮杂鸟嘌呤、1-去氮腺嘌呤、3-去氮腺嘌呤的9-(2-脱氧-β-D-核糖呋喃基)衍生物,5-乙基尿嘧啶、5-氟尿嘧啶的1-(2-脱氧-β-D-核糖呋喃基)衍生物,以及9-(2,3-二脱氧-β-D-戊呋喃基)缺氧嘌呤、9-(2,3-二脱氧-β-D-戊呋喃基)-6-甲基嘌呤和其他核苷酸的验证。
  • Imidazo[4,5-c]pyridines (3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents
    作者:Thomas A. Krenitsky、Janet L. Rideout、Esther Y. Chao、George W. Koszalka、Fred Gurney、Ronald C. Crouch、Naomi K. Cohn、Gerald Wolberg、Ralph Vinegar
    DOI:10.1021/jm00151a022
    日期:1986.1
    A variety of imidazo[4,5-c]pyridines (3-deazapurines) were synthesized. With use of these aglycons as pentosyl acceptors, the corresponding ribonucleosides and 2'-deoxyribonucleosides were prepared by an enzymatic method involving transfer of the pentosyl moiety from appropriate pyrimidine nucleosides. With most of the imidazo[4,5-c]pyridines, the products obtained from the enzyme-catalyzed reactions
    合成了多种咪唑并[4,5-c]吡啶(3-脱氮嘌呤)。使用这些糖苷配基作为戊糖基受体,通过涉及从适当的嘧啶核苷转移戊糖基部分的酶促方法制备相应的核糖核苷和2'-脱氧核糖核苷。对于大多数咪唑并[4,5-c]吡啶,从酶催化反应中获得的产物仅在1-位戊糖基化。然而,在4-位具有H或N 3的糖苷配基发生了一些3-戊糖基化。除了4-氨基-1H-咪唑并[4,5-c]吡啶核糖核苷的2'-脱氧同源物外,还合成了5'-脱氧和2',5'-二脱氧同源物。测试了所有糖苷配基及其核苷对培养物中哺乳动物细胞的毒性。没有一个具有明显的细胞毒性。还评估了这些化合物在体外抑制淋巴细胞介导的细胞溶解的能力。3-Deazaadenosine(23)及其2'-deoxy同系物(38)是最有效的抑制剂(ED50 = 20 microM)。除了这两个体外测试,还确定了大鼠角叉菜胸膜炎模型中炎症反应的体内抑制作用。在该体内测试中,3-脱
查看更多

同类化合物

4-氨基-1-(2’,3’,5’-三-O-叔-丁基二甲基硅烷基-beta-D-呋喃核糖基)-咪唑并[4,5-a]吡啶 3-脱氮腺苷 3-去氮杂鸟苷酸 3-去氮杂鸟苷三磷酸酯 3-去氮杂鸟苷 1-(2-脱氧-beta-D-赤式-呋喃戊糖基)-1H-咪唑并[4,5-c]吡啶-4-胺 1-(2,3,5-三-O-乙酰基-beta-D-呋喃核糖基)-4,6-二氯咪唑并[4,5-c]吡啶 5'-O-(N-L-seryl)sulfamoyl-3-deaza-adenosine 5'-O-(N-glycyl)sulfamoyl-3-deaza-adenosine 5'-O-(N-L-isoleucyl)sulfamoyl-3-deaza-adenosine 2-Fluoro-3-deaza-adenosine 4-(pyridin-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(pyrrol-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(pyrrol-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(furan-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 1-(β-D-ribofuranosyl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine 4-cyclopropyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-methyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 1-(β-D-ribofuranosyl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine Adenosine, 3-deaza- (2R,3S,5R)-5-(4-Dimethylamino-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol (2R,3S,5R)-2-Hydroxymethyl-5-(4-mercapto-imidazo[4,5-c]pyridin-1-yl)-tetrahydro-furan-3-ol 4-chloro-7-fluoro-1-(2'-C-methyl-β-D-ribofuranosyl)-imidazo[4,5-c]pyridine 4-ethyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine (2R,3S,5R)-5-(4-Benzylamino-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol 4-(Methylsulfanyl)-1-pentofuranosyl-1H-imidazo[4,5-c]pyridine 4,7-difluoro-1-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-imidazo[4,5-c]pyridine 6-Chloro-n,n-dimethyl-1-pentofuranosyl-1h-imidazo[4,5-c]pyridin-4-amine 2-(6-Chloro-4-methoxyimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 2-(4-Benzylsulfanyl-6-chloroimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 2-(6-Chloro-4-methylsulfanylimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol N-[4-bromo-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[4,5-c]pyridin-6-yl]acetamide 5,6-Diamino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[4,5-c]pyridin-4-one 1-amino-3-deazaguanosine 3-deazainosine 6-chloro-4-(cyclohexylamino)-1-(3-deoxy-β-D-ribofuranosyl)-1H-imidazo<4,5-c>pyridine [(2R,3R,4R,5R)-3,4-dibenzoyloxy-5-(4,6-dichloroimidazo[4,5-c]pyridin-1-yl)-4-methyloxolan-2-yl]methyl benzoate 4-amino-6-chloro-1-(3-deoxy-β-D-ribofuranosyl)-1H-imidazo<4,5-c>pyridine 4-amino-1-(2-deoxy-b-d-ribofuranosyl)-7-(1-naphthylethynyl)-imidazo[4,5-c]pyridine 3-Deazaguanosine 3',5'-cyclic phosphate 4-chloro-7-fluoro-1-(β-D-ribofuranosyl)imidazo[4,5-c]pyridine (2R,3S,5R)-5-(4-Benzylsulfanyl-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol 4-(1H-pyrazol-5-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 2-bromo-5-methyl-1-(2,3,5-tri-O-t-butyldimethyl-silyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridin-4(5H)-one 4-amino-6-fluoro-1-(2,3,5-tri-O-benzyl-β-D-arabinofuranosyl)imidazo[4,5-c]pyridine 4-amino-6-fluoro-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)imidazo[4,5-c]pyridine 4-chloro-1-(2',3'-dideoxy-α-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-chloro-1-(2',3'-dideoxy-5'-O-<(1'',1 ''-dimethylethyl)dimethylsilyl>-β-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-chloro-1-(2',3'-dideoxy-5'-O-<(1'',1 ''-dimethylethyl)dimethylsilyl>-α-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-(furan-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine